Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
33.30
+0.15 (0.45%)
At close: Apr 14, 2026, 4:00 PM EDT
33.02
-0.28 (-0.85%)
After-hours: Apr 14, 2026, 7:35 PM EDT
Agios Pharmaceuticals Revenue
In the year 2025, Agios Pharmaceuticals had annual revenue of $54.03M with 48.03% growth. Agios Pharmaceuticals had revenue of $19.97M in the quarter ending December 31, 2025, with 86.09% growth.
Revenue (ttm)
$54.03M
Revenue Growth
+48.03%
P/S Ratio
36.11
Revenue / Employee
$100,052
Employees
540
Market Cap
1.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.03M | 17.53M | 48.03% |
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| AnaptysBio | 234.60M |
| Stoke Therapeutics | 184.42M |
| Zymeworks | 105.97M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 51.95M |
AGIO News
- 8 days ago - Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - GlobeNewsWire
- 14 days ago - PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake - GlobeNewsWire
- 14 days ago - Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA - GlobeNewsWire
- 6 weeks ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - GlobeNewsWire
- 2 months ago - Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewsWire
- 3 months ago - Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - GlobeNewsWire
- 3 months ago - Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire